RevitalVision Demonstrates Efficacy, Safety in Infantile Nystagmus - Summary - MDSpire

RevitalVision Demonstrates Efficacy, Safety in Infantile Nystagmus

Positive clinical data shows improvement in visual function in patients with infantile nystagmus

  • By

  • Conexiant News Staff

  • January 13, 2026

  • 1 min

Share

Objective:

To evaluate the efficacy and safety of RevitalVision, a digital therapeutic treatment for infantile nystagmus.

Key Findings:
  • RevitalVision is the first FDA-cleared neuroplasticity-based visual training program for infantile nystagmus.
  • The study provides randomized controlled evidence of improved visual function in patients.
Interpretation:

The findings suggest that RevitalVision may be a viable treatment option for enhancing visual function in individuals with infantile nystagmus.

Limitations:
Conclusion:

The positive clinical data supports the use of RevitalVision as an effective treatment for improving visual function in patients with infantile nystagmus.

Original Source(s)

RevitalVision Demonstrates Efficacy, Safety in Infantile Nystagmus

  • by Conexiant News Staff

  • January 13, 2026

Related Content

Artificial Intelligence: Looking at Large Language Models

Learn about how these programs can help private practices and their related caveats.

Astigmatism Up After COVID Restrictions

Researchers identified delayed corneal changes in schoolchildren that emerged after myopia rates had already increased during the pandemic.

Medical Oddities: Pig Semen, Meet Eye Drops

Evolution, sex, soil, and diets—this lineup covers a little bit of everything.